Biomea Fusion, Inc. Accounts Receivable
Biomea Fusion, Inc. (BMEA) had Accounts Receivable of $36.00 thousand as of 2021-03-31, per its 10-Q filed 2021-05-27.
Discontinued › Balance Sheet › Assets › Assets, Current
us-gaap:AccountsReceivableNetCurrent · last filed 2021-05-27
- 2021-03-31: Accounts Receivable, after Allowance for Credit Loss, Current $36.00K.
- 2020-12-31: Accounts Receivable, after Allowance for Credit Loss, Current $16.00K.
| Period end | Accounts Receivable, after Allowance for Credit Loss, Current |
|---|---|
| 2021-03-31 | $36.00K 10-Q · filed 2021-05-27 |
| 2020-12-31 | $16.00K 10-Q · filed 2021-05-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B |